Propanc Biopharma, Inc. - Common Stock (PPCB)

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset

New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS Therapies

Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia

Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib

Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia

Contrasting Science with Revolution Medicines and Erasca

Accelerates Phase 1b First-in-Human Trial Timeline

Purchasing $500,000 within First 30 days Since Program Commencement

A Promising Strategy for Improving Production for Applications in Biotechnology Research

Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period

Pre-production, Engineering Run and GMP Manufacture of PRP in 2026

Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors

Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing

Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26

Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production

Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that its Board of Directors on March 16, 2026, approved a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share, (the “Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of the open of the market May 18, 2026.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations that Propanc may have issued materially misleading business information to the investing public.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations that Propanc may have issued materially misleading business information to the investing public.

Fifth Agreement between Propanc & the Universities over a 17yr Period

Root-Cause Attack. Chemo Sensitization. Safer Profile.

A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic

PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market